ATLANTA, Nov. 7, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that management will be attending the following investor conferences in November:
-
The 2011 Annual Credit Suisse Health Care Conference to be held November 9 – 11, 2011 at the Arizona Biltmore Hotel in Phoenix, AZ. Dan Myers, president and chief executive officer, and Rick Eiswirth, chief operating officer and chief financial officer, are scheduled to present on Thursday, November 10th at 8:30 A.M.
- The 8th Annual Citi U.S. Small/Mid Cap Conference to be held November 15 – 16, 2011 at the Four Seasons Hotel in Las Vegas, NV. Mr. Myers and Mr. Eiswirth are scheduled to present on Tuesday, November 15th at 8:05 A.M.
The presentation at the Credit Suisse Health Care Conference with accompanying slides will be webcast live and can be accessed on the Investor Relations section of the corporate website at www.alimerasciences.com. For those who are not available to listen to the live broadcast, the Credit Suisse presentation webcast will be archived for 30 days.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, Alimera is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, ILUVIEN, is an investigational intravitreal insert containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.